PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39.30%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-52.92%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-52.92%
Both companies reducing total costs. Martin Whitman would check industry trends.
7.56%
Interest expense growth while RVPH reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
1067.86%
EBITDA growth exceeding 1.5x RVPH's 5.85%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
39.05%
Operating income growth exceeding 1.5x RVPH's 7.11%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-39.05%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-76.41%
Tax expense reduction while RVPH shows 52.58% growth. Joel Greenblatt would examine advantage.
24.67%
Net income growth exceeding 1.5x RVPH's 5.90%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
25.26%
EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
25.26%
Diluted EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.